Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study

被引：0
|
作者：
Lorusso, D. [1 ,2 ]
Xiang, Y. [3 ]
Hasegawa, K. [4 ]
Scambia, G. [2 ,5 ]
Leiva Galvez, M. H. [6 ]
Elias, P. Ramos [7 ]
Acevedo, A. [8 ]
Bednarikova, M. [9 ,10 ]
Gomes, A. J. P. D. S. [11 ]
Mejia, F. Contreras [12 ]
Reiss, A. [13 ]
Zagouri, F. [14 ]
Lee, J-Y. [15 ]
Saevets, V. [16 ]
Ayhan, A. [17 ]
Liu, P. [18 ]
Yamada, K. U. [18 ]
Puglisi, M. [18 ]
Pignata, S. [19 ]
Duska, L. [20 ]
机构：
[1] Fdn Policlin Univ A Gemelli IRCCS, Gynaecol Oncol Unit, Rome, Italy
[2] Univ Cattolica Sacro Cuore, Rome, Italy
[3] Peking Union Med Coll Hosp, Natl Clin Res Ctr Obstetr & Gynecol Dis, Dept Obstet & Gynecol, Beijing, Peoples R China
[4] Saitama Med Univ, Gynecol Oncol Dept, Int Med Ctr, Saitama, Japan
[5] Fdn Policlin Univ A Gemelli IRCCS, Sci Directorate, Rome, Italy
[6] Inst Oncol & Radioterapia Clin Ricardo Palma, Med Oncol, Lima, Peru
[7] Edificio Integra Med Ctr, Integra Canc Inst, Guatemala City, Guatemala
[8] Oncocentro, Med Oncol, Vina Del Mar, Chile
[9] Univ Hosp Brno, Brno, Czech Republic
[10] Masaryk Univ, Fac Med, Brno, Czech Republic
[11] Liga Norte Riograndense Contra O Canc, Med Oncol & Med Oncol Res, Natal, Brazil
[12] Inst Nacl Cancerol, Clin Oncol, Bogota, Colombia
[13] Rambam Med Ctr, Gynecooncol Unit, Haifa, Israel
[14] Alexandra Gen Hosp, Clin Therapeut, Athens, Greece
[15] Yonsei Univ, Severance Hosp, Coll Med, Seoul, South Korea
[16] Chelyabinsk Reg Clin Ctr Oncol & Nucl Med, Dept Gynaecol, Chelyabinsk, Russia
[17] Baskent Univ, Turkish Soc Gynecol Oncol TRSGO, Ankara, Turkey
[18] Merck & Co Inc, Oncol, Rahway, NJ USA
[19] Ist Nazl Tumori IRCCS Fdn G Pascale, Dept Urol & Gynecol, Naples, Italy
[20] Univ Virginia, Obstet & Gynecol, Sch Med, Charlottesville, VA USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.771
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
709O
引用
收藏
页码：S544 / S544
页数：1
相关论文
共 50 条
  • [31] eVOLVE-Cervical (GOG-3092/ENGOT-cx19/GEICO133-C): A prospective phase III study of volrustomig versus placebo after definitive chemoradiation among women with high-risk, locally advanced cervical cancer
    Randall, Leslie
    Wu, Xiaohua
    Mayadev, Jyoti
    Takekuma, Munetaka
    Estevez-Diz, Maria Del Pilar
    Shapira-Frommer, Ronnie
    Rimel, Bobbie
    Lorusso, Domenica
    Lee, Jung-Yun
    Zhou, Qi
    Zeng, Xiaoling
    Huang, Rochelle
    Krug, Lee
    Oaknin, Ana
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S285 - S285
  • [32] Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) in patients (pts) with advanced biliary tract cancer (BTC): results from the randomized, double-blind phase 3 KEYNOTE-966 study
    Pelzer, U.
    Kelley, Kate R.
    Yoo, C.
    Finn, R. S.
    Furuse, J.
    Ren, Z.
    Yau, T.
    Klumpen, H-J
    Chan, S. L.
    Ozaka, M.
    Verslype, C.
    Bouattour, M.
    Park, J. O.
    Barajas, O.
    Valle, J. W.
    Yu, L.
    Malhotra, U.
    Siegel, A. B.
    Edeline, J.
    Ueno, M.
    Vogel, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 61 - 62
  • [33] ENGOT-en11/GOG-3053/KEYNOTE-B21: A phase III study of pembrolizumab or placebo in combination with adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer
    Van Gorp, T.
    Rob, L.
    Lu, W.
    Backes, F.
    Ortac, F.
    Hasegawa, K.
    Hietanen, S. H.
    Savarese, A.
    Laenen, A.
    Kim, Y. M.
    Bodnar, L.
    Barretina Ginesta, M. P.
    Gilbert, L.
    Pothuri, B.
    Chen, X.
    Lichfield, J.
    Wang, W.
    Orlowski, R. J.
    Lortholary, A.
    Slomovitz, B. M.
    ANNALS OF ONCOLOGY, 2024, 35 : 1221 - 1221
  • [34] ENGOT-ov65/KEYNOTE-B96: Phase III, randomized, double-blind study of pembrolizumab vs placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer
    Colombo, N.
    Coleman, R. L.
    Wu, X.
    Kose, F.
    Wenham, R.
    Sebastianelli, A.
    Hasegawa, K.
    Zsiros, E.
    Rouge, T. De La Motte
    Bidzinski, M.
    McNeish, I.
    Sehouli, J.
    Korach, J.
    Debruyne, P. R.
    Kim, J-W.
    De Melo, A. C.
    Peng, X.
    Bogusz, A. M.
    Yamada, K.
    Monk, B. J.
    ANNALS OF ONCOLOGY, 2022, 33 : S400 - S401
  • [35] Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial
    Luke, J.
    Rutkowski, P.
    Queirolo, P.
    Del Vecchio, M.
    Mackiewicz, J.
    Sileni, V. Chiarion
    De la CruzMerino, L.
    Khattak, M. A.
    Schadendorf, D.
    Long, G. V.
    Ascierto, P. A.
    Mandala, M.
    De Galitiis, F.
    Sondak, V.
    Scolyer, R. A.
    Kirkwood, J. M.
    Chen, K.
    Ibrahim, N.
    Ahsan, S.
    Eggermont, A. M. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S1314 - S1315
  • [36] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
    Cortes, Javier
    Guo, Zifang
    Karantza, Vassiliki
    Aktan, Gursel
    CANCER RESEARCH, 2017, 77
  • [37] Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
    Cortes, Javier
    Cescon, David W.
    Rugo, Hope S.
    Nowecki, Zbigniew
    Im, Seock-Ah
    Yusof, Mastura Md
    Gallardo, Carlos
    Lipatov, Oleg
    Barrios, Carlos Henrique
    Perez-Garcia, Jose
    Iwata, Hiroji
    Masuda, Norikazu
    Otero, Marco Torregroza
    Gokmen, Erhan
    Loi, Sherene
    Guo, Zifang
    Zhou, Xuan
    Karantza, Vassiliki
    Pan, Wilbur
    Schmid, Peter
    CANCER RESEARCH, 2022, 82 (04)
  • [38] Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction (mG/ GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study
    Janjigian, Y. Y.
    Kawazoe, A.
    Bai, Y.
    Xu, J.
    Lonardi, S.
    Metges, J-P.
    Weber, P. E. Yanez
    Wyrwicz, L. S.
    Shen, L.
    Ostapenko, Y. V.
    Bilici, M.
    Chung, H. C.
    Shitara, K.
    Qin, S.
    Van Cutsem, E.
    Tabernero, J.
    Li, K.
    Shih, C-S.
    Bhagia, P.
    Rha, S. Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S851 - S852
  • [39] Phase-III-Study for local or locally advanced Prostate Cancer Randomized, double-blind, placebo-controlled Phase-III-Study of Apalutamide in Patients with local High-Risk Prostate Cancer or locally advanced Prostate Cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (02): : 243 - 244
  • [40] KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2-breast cancer
    Cardoso, F.
    Bardia, A.
    Andre, F.
    Cescon, D. W.
    McArthur, H.
    Telli, M.
    Loi, S.
    Cortes, J.
    Schmid, P.
    Harbeck, N.
    Denkert, C.
    Jackisch, C.
    Jia, L.
    Hirshfield, K.
    Karantza, V.
    ANNALS OF ONCOLOGY, 2019, 30
12345